Sabra Health Care REIT, Inc. Announces Chief Investment Officer Transition
Commenting on the CIO transition, Sabra's Chief Executive Officer, President and Chair of the Board, Rick Matros, said, 'Talya has been a critical part of our leadership team since our formation in 2010. Her dedication and exceptional contributions have been invaluable to Sabra's success. She helped build, mentor and lead an incredible team of investment professionals. Thanks to her commitment and leadership, we are well positioned for her upcoming transition to Darrin as our new CIO. Darrin has over 30 years of real estate experience, and his extensive expertise and commitment make him an excellent fit. Darrin has been influential in enhancing the capabilities of our investment team in his five years with Sabra, and we anticipate a seamless transition. The Sabra team and Board look forward to seeing the innovative ideas and leadership he will bring to the table.'
Commenting on her retirement, Ms. Nevo-Hacohen said, 'Building Sabra into a $6.5 billion enterprise with 399 investments from a newly formed REIT with 86 properties leased to a single tenant, has been an incredible journey. I am grateful for the opportunity that I have had to develop personally and professionally as the organization and portfolio have grown. And now, I am excited to pass the baton to Darrin and the rest of our talented and dedicated team and look forward to watching them innovate and drive the evolution of Sabra in the years to come.'
About Sabra
Sabra operates as a self-administered, self-managed real estate investment trust (a 'REIT') that, through its subsidiaries, owns and invests in real estate serving the healthcare industry throughout the United States and Canada.
SOURCE: Sabra Health Care REIT, Inc.
Copyright Business Wire 2025.
PUB: 03/24/2025 09:20 AM/DISC: 03/24/2025 09:22 AM
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
27 minutes ago
- Yahoo
Intel Rallies Despite Fitch Downgrade
Intel (NASDAQ:INTC) got a surprise downgrade from Fitch this week, yet its stock popped about 3.6% anyway. The agency dialed down Intel's long-term credit rating from BBB+ to BBB, pointing to a tougher demand backdrop and the need for debt reduction and stronger product ramps over the next year or two. Short-term ratings stayed at F2, so it's not all doom and gloom. Warning! GuruFocus has detected 6 Warning Signs with INTC. At the same time, Intel's next-gen 18A process is acting up. Early reports suggest Panther Lake chips have roughly three times the defect rate they should, and volume ramps are lagging. That's a headache so close to the planned Q4 launch, especially when smooth ramp-up was supposed to prove we're past the worst of manufacturing woes. Still, investors seem to be looking past the short-term noise. Maybe a rebound in PC and data-center spendingor a clean bill of health at the August 12 bond covenant updatewill do the trick. The real verdict, though, will come with Q3 production progress and any signs that Panther Lake irons out its kinks. This article first appeared on GuruFocus.
Yahoo
27 minutes ago
- Yahoo
Recursion Sets $100 Million Partnership Goal by 202
Recursion (NASDAQ:RXRX) just laid out a roadmap that balances science and cash, and it looks promising. CEO Christopher Gibson talked up how the Exscientia tech and the Boltz-2 partnership with MIT and Nvidia have supercharged their end-to-end platformfrom pinpointing targets to simulating trials. That boost in efficiency shines through in their finances. Warning! GuruFocus has detected 6 Warning Signs with RXRX. CFO Ben Taylor confirmed they finished Q2 with $533 M in the bank and expect to keep burn under $390 M next year. Even better, they're targeting over $100 M in partnership inflows by the end of 2026, which should carry them all the way through Q4 2027 without needing extra financing. On the science side, six internal programs are nearing key milestones. Oncology dose-escalation data should roll in by year-end and rare-disease updates are due early next year. The ClinTech AI platform now promises roughly 50 % faster enrollment projections, and they've hit a fourth Sanofi milestone while rolling out neuronal phenomaps with Roche and Genentech. This article first appeared on GuruFocus.
Business Wire
29 minutes ago
- Business Wire
PERFORMANT HEALTHCARE INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Performant Healthcare, Inc.
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC ('KSF') are investigating the proposed sale of Performant Healthcare, Inc. (NasdaqGS: PHLT) to Machinify. Under the terms of the proposed transaction, shareholders of Performant will receive $7.75 in cash for each share of Performant that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company. If you believe that this transaction undervalues the Company and/or if you would like to discuss your legal rights regarding the proposed sale, you may, without obligation or cost to you, e-mail or call KSF Managing Partner Lewis S. Kahn ( toll free at any time at 855-768-1857, or visit to learn more. To learn more about KSF, whose partners include the Former Louisiana Attorney General, visit
